The regulation of drug compounding is once again a significant issue in health policy discussions. Michael Baker, Director of Health Care Policy, has analyzed the current framework for drug compounding and highlighted how compounded medications, especially GLP-1 drugs, have tested the limits of the regulatory system.
Compounded drugs are typically prepared when an FDA-approved product cannot be used as labeled. This may be necessary if a patient requires a different dosage form, concentration, or needs an ingredient removed due to intolerance. According to Baker, “Traditionally, compounding serves a defined clinical purpose: preparing a medication tailored to a patient’s needs when a Food and Drug Administration-approved product cannot be used as labeled – for example, when a patient needs an alternative dosage form, a different concentration, or the removal of an inactive ingredient that triggers intolerance.”
Recently, there has been a surge in demand for GLP-1 medications. This increase exposed weaknesses in the existing regulations. As Baker notes, “The skyrocketing popularity of GLP-1 medications has revealed how quickly ‘temporary relief’ from the initial FDA-designated shortages can evolve into a parallel consumer market when coverage is uneven and affordability gaps are wide; extended shortages of high-demand injectable products created both the practical and legal predicate for large-scale production of ‘copy’ compounded versions.”
This situation has led to more widespread use of compounded drugs and raised questions about compliance with current laws. Baker points out that “the rapid acceleration of compound drug usage creates real compliance issues with existing laws and highlights the need for targeted reform focused on protecting access to appropriate drugs while reinforcing necessary guardrails.”
Drug compounding is likely to remain under scrutiny as policymakers consider reforms that balance patient access with regulatory safeguards.
